Dynavax Technologies (NASDAQ:DVAX) Shares Down 2.9%

Dynavax Technologies Co. (NASDAQ:DVAX) dropped 2.9% during trading on Tuesday . The stock traded as low as $10.78 and last traded at $10.79. Approximately 188,911 shares traded hands during trading, a decline of 91% from the average daily volume of 2,100,472 shares. The stock had previously closed at $11.11.

Analyst Ratings Changes

Several analysts have recently commented on DVAX shares. The Goldman Sachs Group lowered their price objective on Dynavax Technologies from $20.00 to $15.00 and set a “neutral” rating for the company in a research note on Thursday, August 8th. StockNews.com downgraded shares of Dynavax Technologies from a “buy” rating to a “hold” rating in a research note on Tuesday, May 28th. Finally, HC Wainwright reiterated a “buy” rating and issued a $29.00 price objective on shares of Dynavax Technologies in a research report on Wednesday, August 7th. Two research analysts have rated the stock with a hold rating and three have given a buy rating to the company’s stock. Based on data from MarketBeat, the company has an average rating of “Moderate Buy” and a consensus target price of $23.67.

Dynavax Technologies Stock Down 2.2 %

The company has a quick ratio of 13.18, a current ratio of 14.18 and a debt-to-equity ratio of 0.35. The company has a market capitalization of $1.42 billion, a P/E ratio of 179.83 and a beta of 1.37. The company has a 50 day simple moving average of $11.06 and a two-hundred day simple moving average of $11.45.

Dynavax Technologies (NASDAQ:DVAX) last released its quarterly earnings results on Tuesday, August 6th. The biopharmaceutical company reported $0.08 EPS for the quarter, beating the consensus estimate of $0.06 by $0.02. The business had revenue of $73.80 million during the quarter, compared to analyst estimates of $76.92 million. Dynavax Technologies had a net margin of 6.88% and a return on equity of 2.76%. During the same period in the prior year, the firm posted $0.03 earnings per share. As a group, equities analysts predict that Dynavax Technologies Co. will post 0.16 EPS for the current year.

Institutional Trading of Dynavax Technologies

Institutional investors have recently modified their holdings of the stock. Congress Asset Management Co. MA lifted its holdings in Dynavax Technologies by 0.4% in the fourth quarter. Congress Asset Management Co. MA now owns 227,135 shares of the biopharmaceutical company’s stock valued at $3,175,000 after acquiring an additional 799 shares during the last quarter. Diversified Trust Co grew its position in shares of Dynavax Technologies by 3.2% during the first quarter. Diversified Trust Co now owns 29,548 shares of the biopharmaceutical company’s stock worth $367,000 after buying an additional 925 shares in the last quarter. Zurcher Kantonalbank Zurich Cantonalbank increased its stake in Dynavax Technologies by 1.0% in the second quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 118,037 shares of the biopharmaceutical company’s stock valued at $1,326,000 after purchasing an additional 1,172 shares during the last quarter. SummerHaven Investment Management LLC raised its stake in Dynavax Technologies by 2.4% during the 2nd quarter. SummerHaven Investment Management LLC now owns 54,926 shares of the biopharmaceutical company’s stock worth $617,000 after acquiring an additional 1,303 shares in the last quarter. Finally, Texas Permanent School Fund Corp grew its stake in Dynavax Technologies by 1.3% during the 1st quarter. Texas Permanent School Fund Corp now owns 113,128 shares of the biopharmaceutical company’s stock worth $1,404,000 after buying an additional 1,467 shares during the last quarter. Institutional investors and hedge funds own 96.96% of the company’s stock.

About Dynavax Technologies

Dynavax Technologies Corporation, a commercial stage biopharmaceutical company, focuses on developing and commercializing vaccines in the United States. It markets HEPLISAV-B, a hepatitis B vaccine for prevention of infection caused by all known subtypes of hepatitis B virus in age 18 years and older in the United States and Europe.